Effect of a GnRH Injection on Ghrelin Concentrations in Girls With Suspected Premature Puberty
Primary Purpose
Puberty, Precocious
Status
Completed
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Gonadotropin releasing hormone (GnRH)
Sodium Chloride
Sponsored by
About this trial
This is an interventional basic science trial for Puberty, Precocious focused on measuring females, ghrelin, GnRH, randomized, controlled study, children
Eligibility Criteria
Inclusion Criteria:
- Female gender.
- Clinical suspicion of central precocious puberty.
- A GnRH stimulation test is to be performed to make appropriate diagnosis.
Exclusion Criteria:
- Age < 1 year.
- Weight < 10 kg.
- Untreated hypo- or hyperthyroidism.
- Diabetes of any kind.
- BMI > 3 z-score.
- Growth hormone treatment.
- Syndrome or suspected syndrome.
- Tumour or congenital malformation of the hypothalamus or the pituitary gland. (Neuroradiology does not have to be performed only because of the study.)
- On going ulcus ventriculi or the patient has gone through surgery that removed part of the ventricle or changed it markedly in any other way.
Sites / Locations
- Department of Paediatrics, Örebro University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Gonadotropin releasing hormone (GnRH)
Sodium chloride
Arm Description
A single intravenous injection of gonadotropin releasing hormone GnRH (Relefact LHRH 0,1 mg/mL). Dose: 100 micrograms per square meter body surface. Maximal dose: 100 micrograms.
A single intravenous injection of sodium chlorid (9 mg/mL). Dose: the same volume as the volume given/to be given with GnRH, that is maximal dose = 1 mL = 9 mg sodium chlorid.
Outcomes
Primary Outcome Measures
Ghrelin concentration after GnRH injection and after saline injection
Paired comparison will be done between the acylated ghrelin concentration after GnRH injection and the acylated ghrelin concentration after saline injection.
Paired comparison will also be done between deacylated ghrelin concentration after GnRH injection and deacylated ghrelin concentration after saline injection.
Secondary Outcome Measures
Deacylated ghrelin concentrations in samples treated with the inhibitor AEBSF, in samples treated with both AEBSF and hydrochloric acid, and in samples not treated with either AEBSF or hydrochloric acid
Concentrations of deacylated ghrelin will be compared between different handling procedures.
Deacylated ghrelin concentrations in samples treated with the inhibitor AEBSF, in samples treated with both AEBSF and hydrochloric acid, and in samples not treated with either AEBSF or hydrochloric acid
Deacylated ghrelin concentrations will be compared at 150 min after iv injections between different handling procedures.
Acylated ghrelin concentrations in samples treated with and without hydrochloric acid
Acylated ghrelin concentrations will be compared between different handling procedures.
Full Information
NCT ID
NCT02431416
First Posted
April 10, 2015
Last Updated
March 28, 2019
Sponsor
Region Örebro County
Collaborators
Uppsala-Örebro Regional Research Council
1. Study Identification
Unique Protocol Identification Number
NCT02431416
Brief Title
Effect of a GnRH Injection on Ghrelin Concentrations in Girls With Suspected Premature Puberty
Official Title
Effect of a GnRH Injection on Ghrelin Concentrations in Girls With Suspected Precocious Puberty
Study Type
Interventional
2. Study Status
Record Verification Date
March 2019
Overall Recruitment Status
Completed
Study Start Date
May 2015 (Actual)
Primary Completion Date
December 2017 (Actual)
Study Completion Date
September 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Region Örebro County
Collaborators
Uppsala-Örebro Regional Research Council
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purposes of the study is to investigate whether circulating levels of ghrelin decreases after an iv injection of GnRH in girls with suspected central premature puberty and to investigate the effects of different post sampling handling on the preservation of acylated ghrelin.
Detailed Description
Patients with clinically suspected central premature puberty undergo a GnRH stimulation test to have an appropriate diagnosis. 20 such girls will be recruited to this study and a modified GnRH stimulation test will be done. The modification includes prolonged blood sampling time (0, 30, 60, 90, 120, and 150 min after the GnRH injection instead of the usual 0, 30, 60, and 90 min). The girls will also be investigated twice. In randomised order they will be given either GnRH or placebo (isotone saline), on different days. One week to one month will separate the different investigation days.
The proteinase inhibitor 4-(2-aminoethyl) benzene-sulfonyl fluoride hydrochlorid (AEBSF) will be added to some of the blood tubes, and hydrochloric acid will be added to some of the plasma. All plasma samples will be frozen and all analyses will be done at the same time. Acylated ghrelin will be analyzed by Millipore's specific ELISA kit and deacylated ghrelin will be analyzed by Cayman's specific ELISA kit.
Anthropometric data as well as pubertal state will be collected. P-glucose, S-insulin, S-follicle stimulating hormone (FSH), S-luteinizing hormone (LH), and S-estradiol will also be analyzed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Puberty, Precocious
Keywords
females, ghrelin, GnRH, randomized, controlled study, children
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
13 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Gonadotropin releasing hormone (GnRH)
Arm Type
Active Comparator
Arm Description
A single intravenous injection of gonadotropin releasing hormone GnRH (Relefact LHRH 0,1 mg/mL). Dose: 100 micrograms per square meter body surface. Maximal dose: 100 micrograms.
Arm Title
Sodium chloride
Arm Type
Placebo Comparator
Arm Description
A single intravenous injection of sodium chlorid (9 mg/mL). Dose: the same volume as the volume given/to be given with GnRH, that is maximal dose = 1 mL = 9 mg sodium chlorid.
Intervention Type
Drug
Intervention Name(s)
Gonadotropin releasing hormone (GnRH)
Other Intervention Name(s)
Relefact LHRH
Intervention Description
Gonadotropin releasing hormone GnRH (Relefact LHRH) iv injection, single dose, 100 micrograms/square meter body surface, maximum dose: 100 microgram.
Intervention Type
Drug
Intervention Name(s)
Sodium Chloride
Other Intervention Name(s)
Saline, placebo
Intervention Description
Sodium chlorid 9 mg/mL will be given as a single iv injection with the same volume as the volume used for the active substance injection.
Primary Outcome Measure Information:
Title
Ghrelin concentration after GnRH injection and after saline injection
Description
Paired comparison will be done between the acylated ghrelin concentration after GnRH injection and the acylated ghrelin concentration after saline injection.
Paired comparison will also be done between deacylated ghrelin concentration after GnRH injection and deacylated ghrelin concentration after saline injection.
Time Frame
30-150 min after iv injections
Secondary Outcome Measure Information:
Title
Deacylated ghrelin concentrations in samples treated with the inhibitor AEBSF, in samples treated with both AEBSF and hydrochloric acid, and in samples not treated with either AEBSF or hydrochloric acid
Description
Concentrations of deacylated ghrelin will be compared between different handling procedures.
Time Frame
At baseline
Title
Deacylated ghrelin concentrations in samples treated with the inhibitor AEBSF, in samples treated with both AEBSF and hydrochloric acid, and in samples not treated with either AEBSF or hydrochloric acid
Description
Deacylated ghrelin concentrations will be compared at 150 min after iv injections between different handling procedures.
Time Frame
150 min after iv injections
Title
Acylated ghrelin concentrations in samples treated with and without hydrochloric acid
Description
Acylated ghrelin concentrations will be compared between different handling procedures.
Time Frame
0-150 min after iv injections
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
1 Year
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female gender.
Clinical suspicion of central precocious puberty.
A GnRH stimulation test is to be performed to make appropriate diagnosis.
Exclusion Criteria:
Age < 1 year.
Weight < 10 kg.
Untreated hypo- or hyperthyroidism.
Diabetes of any kind.
BMI > 3 z-score.
Growth hormone treatment.
Syndrome or suspected syndrome.
Tumour or congenital malformation of the hypothalamus or the pituitary gland. (Neuroradiology does not have to be performed only because of the study.)
On going ulcus ventriculi or the patient has gone through surgery that removed part of the ventricle or changed it markedly in any other way.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maria Lodefalk, MD, PhD
Organizational Affiliation
Department of Paediatrics, Faculty of Medicine and Health, Örebro University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Paediatrics, Örebro University Hospital
City
Örebro
ZIP/Postal Code
701 85
Country
Sweden
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effect of a GnRH Injection on Ghrelin Concentrations in Girls With Suspected Premature Puberty
We'll reach out to this number within 24 hrs